GlassScriptPhysician profile
Mohsen Ibrahim Ali
NPI 1750359071
$8,140.85
in general payments reported to CMS, 2019-2025
40 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $699 · 2021: $694 · 2022: $1,205 · 2023: $1,557 · 2024: $1,525 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796 · Education: $138 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,795.85 |
| Education | $138.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.66 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $686.25 | 2019-2025 | Nayzilam, Fintepla, Rystiggo |
| Amgen INC. | $520.35 | 2019-2023 | Aimovig |
| Argenx US, INC. | $499.93 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $441.14 | 2023-2025 | |
| Biogen, INC. | $364.94 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Allergan, INC. | $355.76 | 2019-2022 | |
| Celgene Corporation | $307.33 | 2023-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $238.54 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $235.73 | 2021-2023 | Ponvory |
| Novartis Pharmaceuticals Corporation | $231.85 | 2019-2024 | |
| Lundbeck LLC | $213.72 | 2024-2025 | Vyepti |
| Akcea Therapeutics, INC. | $205.17 | 2019-2020 | |
| Grifols USA, LLC | $199.64 | 2023-2024 | Gamunex-C |
| Mdd US Operations, LLC | $195.75 | 2023-2025 | Gocovri, Gocovri |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.